PHASE-II STUDY OF PENTOSTATIN AND INTERMITTENT HIGH-DOSE RECOMBINANT INTERFERON ALFA-2A IN ADVANCED MYCOSIS-FUNGOIDES SEZARY-SYNDROME

被引:71
作者
FOSS, FM
IHDE, DC
BRENEMAN, DL
PHELPS, RM
FISCHMANN, AB
SCHECHTER, GP
LINNOILA, I
BRENEMAN, JC
COTELINGAM, JD
GHOSH, BC
STEINBERG, SM
LYNCH, JW
PHARES, JC
STOCKER, JL
BASTIAN, A
SAUSVILLE, EA
机构
[1] USN HOSP, NCI, BETHESDA, MD 20814 USA
[2] UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA
[3] VET AFFAIRS MED CTR, WASHINGTON, DC USA
[4] GEORGE WASHINGTON UNIV, WASHINGTON, DC 20052 USA
[5] UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA
关键词
D O I
10.1200/JCO.1992.10.12.1907
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This phase II study was undertaken to assess the efficacy and toxicity of alternating administration of pentostatin (deoxycoformycin [DCF]) and Interferon alfa-2a (IFN) in patients with advanced or refractory mycosis fungoides (MF) or the Sézary syndrome (SS). Patients and Methods: Forty-one patients underwent therapy with alternating cycles of DCF 4 mg/m2 intravenously (IV) days 1 through 3 and IFN 10 million U/m2 intramuscularly (IM) day 22, and 50 million U/m2 intramuscularly (IM) days 23 through 26. Twenty-nine patients had not responded to prior chemotherapy or total-skin electron-beam irradiation (TSEB), six had not responded to topical therapies, and six had no previous treatment. Results: Two patients achieved a complete response (CR) and 15 achieved a partial response (PR), for an overall response rate of 41% (95% confidence interval, 26% to 58%). No responses were observed in the seven patients with visceral involvement. The median progression-free survival of patients who responded was 13.1 months. IFN-related constitutional symptoms were reported in 39% of patients; severe toxicities included cardiomyopathy in one patient, acute and chronic pulmonary dysfunction in four, and reversible mental status changes in two. Seven patients developed herpes zoster during therapy and six had staphylococcal bacteremia. Conclusion: These results suggest that the combination of DCF and IFN is an active regimen in MF patients without visceral involvement.
引用
收藏
页码:1907 / 1913
页数:7
相关论文
共 48 条
  • [21] KEATING MJ, 1988, NOUV REV FR HEMATOL, V30, P461
  • [22] PHASE-II TRIAL OF INTERMITTENT HIGH-DOSE RECOMBINANT INTERFERON-ALFA-2A IN MYCOSIS-FUNGOIDES AND THE SEZARY SYNDROME
    KOHN, EC
    STEIS, RG
    SAUSVILLE, EA
    VEACH, SR
    STOCKER, JL
    PHELPS, R
    FRANCO, S
    LONGO, DL
    BUNN, PA
    IHDE, DC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) : 155 - 160
  • [23] IMMUNOSUPPRESSIVE EFFECTS OF PENTOSTATIN
    KRAUT, EH
    NEFF, JC
    BOURONCLE, BA
    GOCHNOUR, D
    GREVER, MR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (05) : 848 - 855
  • [24] LONG JC, 1974, CANCER, V34, P1745, DOI 10.1002/1097-0142(197411)34:5<1745::AID-CNCR2820340524>3.0.CO
  • [25] 2-W
  • [26] CUTANEOUS T-CELL LYMPHOMAS - SEZARY SYNDROME, MYCOSIS-FUNGOIDES, AND RELATED DISORDERS
    LUTZNER, M
    EDELSON, R
    SCHEIN, P
    GREEN, I
    KIRKPATRICK, C
    AHMED, A
    [J]. ANNALS OF INTERNAL MEDICINE, 1975, 83 (04) : 534 - 552
  • [27] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
  • [28] TREATMENT OF HAIRY-CELL LEUKEMIA WITH ALTERNATING CYCLES OF PENTOSTATIN AND RECOMBINANT LEUKOCYTE-A INTERFERON - RESULTS OF A PHASE-II STUDY
    MARTIN, A
    NERENSTONE, S
    URBA, WJ
    LONGO, DL
    LAWRENCE, JB
    CLARK, JW
    HAWKINS, MJ
    CREEKMORE, SP
    SMITH, JW
    STEIS, RG
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (04) : 721 - 730
  • [29] TOTAL SKIN ELECTRON-BEAM AND TOTAL NODAL IRRADIATION FOR TREATMENT OF PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA
    MICAILY, B
    VONDERHEID, EC
    BRADY, LW
    ANDREWS, C
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (06): : 1111 - 1115
  • [30] 2'-DEOXYCOFORMYCIN (PENTOSTATIN) FOR LYMPHOID MALIGNANCIES - RATIONAL DEVELOPMENT OF AN ACTIVE NEW DRUG
    ODWYER, PJ
    WAGNER, B
    LEYLANDJONES, B
    WITTES, RE
    CHESON, BD
    HOTH, DF
    [J]. ANNALS OF INTERNAL MEDICINE, 1988, 108 (05) : 733 - 743